| Objective:To investigate the expression of BCL 11 A gene in breast cancer, analyze the relationship between BCL 11 A and the occurrence and development of breast cancer and its clinical significance.Methods:(1) Molecular typing is carried out for collected breast tissues according to the expression difference of ER, PR and Her-2. It is divided into 4 categories, i.e., luminal A, luminal B, basal cell and Her-2 over-expression, every categories is 11 cases.Real-time quantitative polymerasechain reaction(RT-qPCR) is adopted to technologically test the expressions of 44 breast cancer cases and BCL 11 A mRNA in16 normal breast tissues.(2) Applying immunohistochemistry chemical staining to testing the expression of BCL 11 A protein of 44 breast cancer and 16 normal breast tissues adopted in RT-PCR experiments. Moreover, the paper analyzes its correlation to expressions of BCL 11 A mRNA. At the same time, 78 breast cancer tissues are tested,including 6luminal A cases, 7 luminal B cases, 9 basal cell cases and 56 Her-2 over-expression cases,and then analysis is carried out for the relationship between BCL 11 A protein and molecular typing of breast cancer and other clinical pathological parameters.Results:(1) It is found that BCL 11 A mRNA is expressed in luminal A, luminal B, basal cell and Her-2 over-expression breast cancer and normal breast tissues. The expression of basal breast cancers is higher than other molecular typing breast cancer and normal breast tissues(P<0.05).(2) The expression of BCL 11 A protein is related to the expression of mRNA.The higher the expression of BCL 11 A mRNA is, the higher the expression of BCL11 Aprotein is(P<0.05).(3) According to immunohistochemistry, BCL 11 A protein’s nucleus and cytoplasm take on positive expression in breast cancer. Moreover, in the basal cellbreast cancer(49/67), its expression is obviously higher than luminal A(3/17),luminal B(3/18), and Her-2 over-expression(4/20). The difference is of statistical significance(P<0.05).(4) The expression of BCL 11 A protein is related to the expression of histological grade, lymph node metastasis, molecular typing and estrogen receptor(ER), protrogen receptor(PR) and human epidermal receptor(HER-2). The expression of BCL 11 A protein in histological grade level III group is higher than I and II. The difference is of statistical significance(P<0.05). There is no obvious difference between histological grade level I and level II(P<0.05). Its expression in lymph node metastasis group is higher than that in non-lymph node metastasis. The difference is of statistical significance(P<0.05). Its expression in basal subtype group is higher than that luminal A,luminal B and HER2 subtypes group. The difference is of statistical significance(P<0.05). Its expression in ER-negative group is higher than that in ER-positive group. The difference is of statistical significance(P<0.05). Its expression in PR-negative group is higher than that in PR-positive group, The difference is of statistical significance(P<0.05). Its expression in Her-2-negative group is higher than that in Her-2-positive group. The difference is of statistical significance(P<0.05). There is no obvious correlation between patients’ age and tumor size.Conclusion:(1) High expression of BCL 11 A mRNA and protein in breast cancer, especially in basal cell sample breast cancer, the expression of mRNA and protein is obviously higher than other-molecular typing breast cancer, which indicates BCL 11A’s important role in the occurrence of basal cell-like breast cancer. It shows a new indication for the identification of breast cancer and prognosis of patients. Inhibiting BCL11 A gene might be a new targeted therapy object, which is of important significance to improve breast cancer patients.(2) The expression of BCL 11 A protein is related to histological grade and lymph node metastasis of breast cancer, which indicates that BCL 11 A protein is one factor possibly affecting the tumor differentiation and invasion and metastasis ofbreast cancer. |
PDF Full Text Request